Filing Overview
This Form 8-K was filed by Tivic Health Systems, Inc. on June 16, 2023, reporting events occurring June 14, 2023. The request metadata identifies Valion Bio, Inc., but the filing identifies Tivic Health Systems, Inc. as the registrant, ticker TIVC.
Business Context and Reporting Period
The filing reports the reconvened portion of Tivic Health’s 2023 Annual Meeting of Stockholders and the grant of stock options to non-executive directors. It does not present operating or financial results for a reporting period.
Key Financial and Capitalization Information
- As of the April 13, 2023 record date, 29,677,734 shares of common stock were issued and outstanding.
- At the reconvened meeting, 16,310,348 shares, or approximately 55% of outstanding shares, were represented, constituting a quorum.
- The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics.
Material Changes and Corporate Actions
- Class II director elected: Dean Zikria was elected to serve until the 2026 annual meeting or until a successor is elected and qualified.
- Reverse stock split proposal rejected: Stockholders did not approve authorization for the Board to implement, at its discretion within 12 months, a reverse split ranging from 1-for-5 to 1-for-30. The proposal received 14,000,037 votes for, 2,153,285 against, and 157,026 abstentions, but approval required a majority of all outstanding shares. The filing states that votes for represented approximately 47% of outstanding shares.
- Auditor ratified: Stockholders ratified Rosenberg Rich Baker Berman, P.A. as the independent registered public accounting firm for fiscal 2023, with 15,466,407 votes for, 727,906 against, and 116,035 abstentions.
- Director option grants: Each non-executive director received options to purchase 25,000 shares at $0.093 per share, the June 14 closing price. The options expire after 10 years and vest 50% after one year, 25% after two years, and 25% after three years.
Guidance, Outlook, Risks, and Unusual Items
- The filing provides no financial guidance or management outlook.
- The failed reverse stock split authorization may limit the Board’s ability to respond to share-price or listing-related considerations through a reverse split without seeking additional stockholder approval.
- The filing does not identify specific contingencies, litigation matters, or liquidity risks.
- The director option grants will create potential future equity dilution and compensation expense, although the filing does not quantify the accounting impact.
Important Facts to Verify
- Confirm that the intended company is Tivic Health Systems, Inc. rather than Valion Bio, Inc.
- Review the April 24, 2023 definitive proxy statement for the full terms and rationale of the reverse stock split proposal.
- Verify the number of non-executive directors receiving the 25,000-share option grants and the resulting aggregate potential dilution.
- Monitor future filings for any renewed reverse stock split proposal, Nasdaq compliance developments, or changes in capitalization.